Medium-Chain Fatty Acids Released from Polymeric Electrospun Patches Inhibit Candida albicans Growth and Reduce the Biofilm Viability
Source abstract
Abstract
Oral candidiasis is a very common oral condition among susceptible individuals, with the main causative organism being the fungus Candida albicans. Current drug delivery systems to the oral mucosa are often ineffective because of short drug/ tissue contact times as well as increased prevalence of drugresistant Candida strains. We evaluated the potency of saturated fatty acids as antifungal agents and investigated their delivery by novel electrospun mucoadhesive oral patches using agar disk diffusion and biofilm assays. Octanoic (C8) and nonanoic (C9) acids were the most effective at inhibiting C. albicans growth on disk diffusion assays, both in solution or when released from polycaprolactone (PCL) or polyvinylpyrrolidone/RS100 (PVP/ RS100) electrospun patches. In contrast, dodecanoic acid (C12) displayed the most potent antifungal activity against pre-existing C. albicans biofilms in solution or when released by PCL or PVP/RS100 patches. Both free and patch-released saturated fatty acids displayed a significant toxicity to wild-type and azole-resistant strains of C. albicans. These data not only provide evidence that certain saturated fatty acids have the potential to be used as antifungal agents but also demonstrate that this therapy could be delivered directly to Candida-infected sites using electrospun mucoadhesive patches, demonstrating a potential new therapeutic approach to treat oral thrush.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Antifungal resistance and susceptibility · Oral microbiology and periodontitis research · HIV/AIDS oral health manifestations
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Clinical Dentistry, University of Sheffield, 19 Claremont Crescent, Sheffield S10 2TA, U.K.
Afyx Therapeutics, Lergravsej 57, 2. tv, 2300 Copenhagen, Denmark
Department of Chemistry, University of Sheffield, Brook Hill, Sheffield S3 7HF, U.K.
Funding
Engineering and Physical Sciences Research Council · AFYX Therapeutics
References (47)
Show source-provided references
1. 10.3109/1040841870910444410.3109/10408418709104444 ↗
2. 10.1038/sj.bdj.2017.88610.1038/sj.bdj.2017.886 ↗
3. 10.1002/1097-0142(19881101)62:9<2042::aid-cncr2820620928>3.0.co;2-d10.1002/1097-0142(19881101)62:9<2042::aid-cncr2820620928>3.0.co;2-d ↗
4. 10.1080/0268121928000073110.1080/02681219280000731 ↗
5. 10.1111/j.1574-695X.1995.tb00077.x10.1111/j.1574-695X.1995.tb00077.x ↗
6. 10.1086/42194610.1086/421946 ↗
7. 10.1177/15441113030140040310.1177/154411130301400403 ↗
8. 10.1111/j.1532-849X.2011.00698.x10.1111/j.1532-849X.2011.00698.x ↗
9. 10.3389/fmed.2016.0001110.3389/fmed.2016.00011 ↗
10. 10.1177/0022034501080003110110.1177/00220345010800031101 ↗
11. 10.1038/srep2357510.1038/srep23575 ↗
12. 10.1016/J.CBI.2014.12.01410.1016/J.CBI.2014.12.014 ↗
13. 10.1038/srep0965710.1038/srep09657 ↗
14. 10.1371/journal.pone.018127810.1371/journal.pone.0181278 ↗
15. 10.1371/journal.pone.016747010.1371/journal.pone.0167470 ↗
16. Pohl C. H. · 2011 · 3 · 61
17. 10.1248/bpb.27.132110.1248/bpb.27.1321 ↗
18. 10.1128/AEM.67.2.956-960.200110.1128/AEM.67.2.956-960.2001 ↗
19. 10.1371/journal.pone.001205010.1371/journal.pone.0012050 ↗
20. 10.1111/j.1365-2672.1991.tb02956.x10.1111/j.1365-2672.1991.tb02956.x ↗
21. 10.4317/jced.5179810.4317/jced.51798 ↗
22. 10.1016/j.clindermatol.2016.02.02210.1016/j.clindermatol.2016.02.022 ↗
23. 10.1021/acsami.7b0233710.1021/acsami.7b02337 ↗
24. 10.1016/j.biomaterials.2018.06.00910.1016/j.biomaterials.2018.06.009 ↗
25. 10.1021/acs.molpharmaceut.9b0053510.1021/acs.molpharmaceut.9b00535 ↗
26. 10.1016/j.biomaterials.2008.01.01110.1016/j.biomaterials.2008.01.011 ↗
27. 10.1038/nmeth.208910.1038/nmeth.2089 ↗
28. 10.1093/infdis/172.4.115310.1093/infdis/172.4.1153 ↗
29. 10.1128/jcm.34.9.2154-2157.199610.1128/jcm.34.9.2154-2157.1996 ↗
30. 10.1128/jcm.37.12.3856-3859.199910.1128/jcm.37.12.3856-3859.1999 ↗
31. 10.1016/j.ijpharm.2007.11.02910.1016/j.ijpharm.2007.11.029 ↗
32. 10.1016/j.semcdb.2018.02.02610.1016/j.semcdb.2018.02.026 ↗
33. 10.1016/j.archoralbio.2011.01.01110.1016/j.archoralbio.2011.01.011 ↗
34. 10.1128/AAC.2.1.2310.1128/AAC.2.1.23 ↗
35. 10.1128/aac.45.11.3209-3212.200110.1128/aac.45.11.3209-3212.2001 ↗
36. 10.5582/ddt.2015.0106210.5582/ddt.2015.01062 ↗
37. 10.1128/JCM.41.7.2961-2967.200310.1128/JCM.41.7.2961-2967.2003 ↗
38. 10.1128/AAC.45.9.2475-2479.200110.1128/AAC.45.9.2475-2479.2001 ↗
39. 10.1007/BF0252246510.1007/BF02522465 ↗
40. 10.1128/aac.44.10.2873-2875.200010.1128/aac.44.10.2873-2875.2000 ↗
41. 10.1111/j.1365-2958.2007.06013.x10.1111/j.1365-2958.2007.06013.x ↗
42. 10.1016/j.solmat.2008.05.01310.1016/j.solmat.2008.05.013 ↗
43. 10.1177/155892501882489010.1177/1558925018824890 ↗
44. 10.1016/j.carbpol.2015.06.03210.1016/j.carbpol.2015.06.032 ↗
45. 10.1016/j.colsurfb.2014.12.00910.1016/j.colsurfb.2014.12.009 ↗
46. 10.1007/s11095-013-1291-110.1007/s11095-013-1291-1 ↗
47. 10.1016/j.msec.2014.07.02810.1016/j.msec.2014.07.028 ↗